|
| 37319016 | A Pharmacological Evaluation of the Analgesic Effect and Hippocampal Protein Modulation of the Ketamine Metabolite (2R,6R)-Hydroxynorketamine in Murine Pain Models. | Anesth Analg | 2024 |
| 36883564 | mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer. | JCI Insight | 2023 |
| 37858338 | High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma. | Cell Rep Med | 2023 |
| 37627061 | Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma. | Cancers (Basel) | 2023 |
| 37616468 | Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models. | Clin Cancer Res | 2023 |
| 35732692 | The show must go on. Reply to "Distinct functions of S-ketamine and R-ketamine in mediating biobehavioral processes of drug dependency: comments on Bonaventura et al" by Insop Shim. | Mol Psychiatry | 2023 |
| 37353483 | Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex. | Nat Commun | 2023 |
| 37216280 | Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication. | Mol Cancer Ther | 2023 |
| 37054779 | Preclinical validation of a novel therapeutic strategy for choroid plexus carcinoma. | J Control Release | 2023 |
| 37348462 | Positional influence on cellular transcriptional identity revealed through spatially segmented single-cell transcriptomics. | Cell Syst | 2023 |
| 37380628 | A landscape of response to drug combinations in non-small cell lung cancer. | Nat Commun | 2023 |
| 37172199 | Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML. | Blood | 2023 |
| 37141112 | Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. | Cancer Discov | 2023 |
| 37140427 | CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations. | Cancer Res | 2023 |
| 37095531 | High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma. | J Exp Clin Cancer Res | 2023 |
| 37356470 | Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma. | Cancer Lett | 2023 |
| 34624079 | SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. | Blood | 2022 |
| 35511749 | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | Mol Cancer Ther | 2022 |
| 35584006 | Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma. | Cancer Res | 2022 |
| 35768639 | Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search. | Mol Psychiatry | 2022 |
| 35702394 | The Remarkable Selectivity of Nirmatrelvir. | ACS Pharmacol Transl Sci | 2022 |
| 35501309 | Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration. | Transl Psychiatry | 2022 |
| 35754026 | Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma. | J Exp Clin Cancer Res | 2022 |
| 35752173 | Methionine oxidation activates pyruvate kinase M2 to promote pancreatic cancer metastasis. | Mol Cell | 2022 |
| 36192480 | Publisher Correction: Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma. | Nat Commun | 2022 |
| 36115844 | Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma. | Nat Commun | 2022 |
| 35030628 | Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma. | Blood Adv | 2022 |
| 35113535 | Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2<i>,</i>6)- and (5<i>R</i>)-Methyl-(2<i>R,</i>6<i>R</i>)-hydroxynorketamines. | ACS Chem Neurosci | 2022 |
| 35194167 | Time will tell. Reply to "Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al." by Chen et al. | Mol Psychiatry | 2022 |
| 33382985 | Increased demand for NAD<sup>+</sup> relative to ATP drives aerobic glycolysis. | Mol Cell | 2021 |
| 33848478 | Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. | Cancer Cell | 2021 |
| 33674359 | Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications. | Pharmacol Rev | 2021 |
| 33859356 | Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. | Mol Psychiatry | 2021 |
| 33801811 | Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo. | Microorganisms | 2021 |
| 34778802 | Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. | Blood Cancer Discov | 2021 |
| 34296206 | KiRNet: Kinase-centered network propagation of pharmacological screen results. | Cell Rep Methods | 2021 |
| 34264955 | Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. | PLoS One | 2021 |
| 33945878 | A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801. | Neurotoxicol Teratol | 2021 |
| 33158997 | Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma. | Mol Cancer Ther | 2021 |
| 33271120 | Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. | Immunity | 2021 |
| 33184494 | A novel model of alternative NF-κB pathway activation in anaplastic large cell lymphoma. | Leukemia | 2021 |
| 33129109 | Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia. | Transl Oncol | 2021 |
| 32371575 | EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth. | Mol Cancer Ther | 2020 |
| 33334024 | Matrix Drug Screen Identifies Synergistic Drug Combinations to Augment SMAC Mimetic Activity in Ovarian Cancer. | Cancers (Basel) | 2020 |
| 33147485 | Multi-Tissue Acceleration of the Mitochondrial Phosphoenolpyruvate Cycle Improves Whole-Body Metabolic Health. | Cell Metab | 2020 |
| 32575908 | Drugs Targeting Tumor-Initiating Cells Prolong Survival in a Post-Surgery, Post-Chemotherapy Ovarian Cancer Relapse Model. | Cancers (Basel) | 2020 |
| 32998994 | Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer. | Cancer Res | 2020 |
| 32642733 | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Neurooncol Adv | 2020 |
| 32611550 | Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9. | Mol Cancer Res | 2020 |
| 32149729 | Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. | J Clin Invest | 2020 |